Octreotide needle-free injectable - Glide/Endo

Drug Profile

Octreotide needle-free injectable - Glide/Endo

Alternative Names: Glide octreotide; GP-02; Octreotide SDI

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Glide Pharma
  • Developer Endo International; Glide Pharma; Glide Technologies
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acromegaly

Most Recent Events

  • 28 Jun 2016 Glide Technologies completes a phase I trial in Acromegaly in United Kingdom (SC)
  • 19 May 2016 Phase-I clinical trials in Acromegaly in United Kingdom (SC)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top